A Phase II trial to Evaluate the Efficacy and Safety of

OKN-007 Combined with Temozolomide (TMZ)

in Patients with Recurrent Glioblastoma

Key Inclusion Criteria:

  • Confirmed recurrent GBM, following primary treatment with TMZ and radiotherapy (at least two cycles of maintenance TMZ) : Patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be GBM and the patient received prior radiochemotherapy
  • Patients must be ≥18 years of age

Key Exclusion Criteria:

  • Early discontinuation of TMZ in first line due to treatment related adverse events
  • Patients receiving or planning to initiate treatment with the tumor treating fields device, Optune®
    (Optune® treatment prior to enrollment is permitted)

For more information, click here.

For your participation in the study, contact Oblato or the nearest institution below:

For your participation in the study, contact Oblato or the nearest institution below:

Sponsor, Oblato

Contact: Alex E. Kim, Project Manager     609-734-4329     Alex@oblatoinc.com

United States, Alabama

University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Contact: Thiru Pillay    205-934-1432    tpillay@uabmc.edu
Sub-Investigator: Louis Burt Nabors, MD

United States, Arizona

St. Joseph’s Hospital and Medical Center
Phoenix, Arizona, United States, 85013
Contact: Katy Gilbert       Kathryn.Gilbert@DignityHealth.org
Principal Investigator: Ekokobe Fonkem, DO

United States, California

Providence Saint John’s Health Center – John Wayne Cancer Institute
Santa Monica, California, United States, 90404
Contact: Ashley Archer    310-582-7460    Ashley.Archer@providence.org
Principal Investigator: Santosh Kesari, MD, PhD
Sub-Investigator: Naveed Wagle, MD

United States, Colorado

Swedish Medical Center
Englewood, Colorado, United States, 80113
Contact: Judith Stucky       Judith.Stucky@HCAhealthcare.com
Principal Investigator: Michael Pearlman, MD

United States, Michigan

Henry Ford Health System
Detroit, Michigan, United States, 48202
Contact: Stephanie Mintoff       Smintof1@hfhs.org
Principal Investigator: Tobias Walbert, MD, PhD

United States, North Carolina

Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157
Contact: Ashley Carroll       arcarrol@wakehealth.edu
Principal Investigator: Glenn Lesser, MD

United States, Ohio

The University of Toledo
Toledo, Ohio, United States, 43606
Contact: Stephanie Smiddy       stephanie.smiddy@utoledo.edu
Principal Investigator: Roland Skeel, MD

United States, Oklahoma

The University of Oklahoma
Oklahoma City, Oklahoma, United States, 73117
Contact: Hee Sun Kim-Suh       HeeSun-Kim@ouhsc.edu
Principal Investigator: James Battiste, MD, PhD